Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) is anticipated to issue its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $12.9440 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Trading Down 2.4%

Shares of NASDAQ:AQST opened at $6.84 on Monday. The business has a 50-day moving average price of $5.37 and a 200 day moving average price of $4.01. The company has a market capitalization of $682.08 million, a price-to-earnings ratio of -9.77 and a beta of 1.77. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $7.55.

Analyst Ratings Changes

AQST has been the subject of a number of recent analyst reports. JMP Securities raised their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th. Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $10.33.

Insider Transactions at Aquestive Therapeutics

In other news, CEO Daniel Barber sold 91,343 shares of Aquestive Therapeutics stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $6.03, for a total value of $550,798.29. Following the completion of the transaction, the chief executive officer owned 923,430 shares in the company, valued at approximately $5,568,282.90. This trade represents a 9.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Carl N. Kraus sold 20,272 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total value of $141,904.00. Following the completion of the transaction, the insider owned 282,475 shares of the company’s stock, valued at $1,977,325. The trade was a 6.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 276,770 shares of company stock valued at $1,692,203. Insiders own 7.85% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after buying an additional 2,649 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Aquestive Therapeutics by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock valued at $106,000 after buying an additional 4,557 shares during the period. Modern Wealth Management LLC purchased a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at about $33,000. Finally, Creative Planning boosted its stake in shares of Aquestive Therapeutics by 15.3% in the 2nd quarter. Creative Planning now owns 98,751 shares of the company’s stock valued at $327,000 after buying an additional 13,130 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.